<code id='772F868E27'></code><style id='772F868E27'></style>
    • <acronym id='772F868E27'></acronym>
      <center id='772F868E27'><center id='772F868E27'><tfoot id='772F868E27'></tfoot></center><abbr id='772F868E27'><dir id='772F868E27'><tfoot id='772F868E27'></tfoot><noframes id='772F868E27'>

    • <optgroup id='772F868E27'><strike id='772F868E27'><sup id='772F868E27'></sup></strike><code id='772F868E27'></code></optgroup>
        1. <b id='772F868E27'><label id='772F868E27'><select id='772F868E27'><dt id='772F868E27'><span id='772F868E27'></span></dt></select></label></b><u id='772F868E27'></u>
          <i id='772F868E27'><strike id='772F868E27'><tt id='772F868E27'><pre id='772F868E27'></pre></tt></strike></i>

          Home / comprehensive / focus

          focus


          focus

          author:explore    Page View:21
          Adobe

          LONDON — GSK said Tuesday it would purchase the asthma-focused drug developer Aiolos Bio for $1 billion upfront, the latest in a string of pharma acquisitions that are bolstering hopes for the industry’s year ahead.

          The deal includes up to another $400 million in payments if certain milestones are met.

          advertisement

          Aiolos was launched just last year, based in both San Francisco and London. The company, which announced a $245 million Series A round in October, has been readying a Phase 2 trial of its candidate AIO-001 in adult asthma.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In